Shares of Guardant Health Inc. (GH) surged 6.48% in Thursday's trading session following the company's release of better-than-expected first-quarter 2025 financial results and an increase in its full-year revenue guidance.
The precision oncology company reported a narrower-than-anticipated loss for Q1, with adjusted earnings per share of $(0.49), significantly beating the analyst consensus estimate of $(0.81). Revenue for the quarter came in at $203.47 million, surpassing Wall Street expectations of $190.16 million and marking a robust 20.76% increase compared to the same period last year.
Guardant Health's strong performance was driven by growth across its business segments. Oncology revenue grew 20% to $150.6 million, while biopharma and data revenue increased 21% to $45.4 million. The company also reported progress in its screening business, with 9,000 Shield screening tests performed during the quarter.
In light of the strong Q1 results, Guardant Health raised its full-year 2025 revenue guidance to a range of $880 million to $890 million, representing growth of 19% to 20% compared to 2024. This updated outlook exceeded previous analyst expectations and likely contributed to the positive investor sentiment driving the stock's upward movement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.